ClinicalTrials.gg
CompletedNCT07532187Updated Oct 21, 2026

The Effects of Extracorporeal Shock Wave Therapy on Upper Extremity Spasticity and Function in Patients With Stroke

An interventional study of Radial Extracorporeal Shock Wave Therapy (rESWT) in Stroke, sponsored by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2025, registered Apr 2026).
Updated Oct 21, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 487 studies in Stroke with a site in Turkey — 96 open to participants now, 109 under way, 3 of them phase 3. Stroke · Turkey.

Enrollment
219th of 323
30 · median 40
Started
2025
with 70 others
No phase
294 of 487
58 open now
Registered
435th of 487
by date

Among the 487 studies in Stroke with a site in Turkey, this one is the 219th largest by enrollment of the 323 interventional ones that give a count, is one of 71 that started in 2025, is one of 294 with no phase, and was the 435th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

96 of the 487 studies in Stroke with a site in Turkey are open now. Recruiting first, the newest first:

91 more — sign in →

All 96 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 487 studies in Stroke with a site in Turkey, or all of them as a file.
02

Study summary

Spasticity is a common complication after stroke and can limit upper extremity motor control and activities of daily living. Radial extracorporeal shock wave therapy (rESWT) is a non-invasive treatment that has been investigated for post-stroke spasticity; however, treatment protocols vary widely across studies in the muscles treated, number of impulses, session frequency, energy parameters, and application sites. This prospective, single-center, single-arm study enrolled 30 adults with post-stroke hemiplegia and upper extremity spasticity to evaluate changes in clinical outcomes following an rESWT protocol with anatomically predefined target points. rESWT was applied to the biceps brachii, flexor carpi radialis, and flexor carpi ulnaris of the affected arm twice weekly for 4 weeks (8 sessions). Spasticity, upper extremity motor function, functional independence, quality of life, pain, depressive symptoms, and sensory findings were assessed at baseline, week 4, and week 12.

Read the detailed description

Rationale: Studies of extracorporeal shock wave therapy for post-stroke spasticity differ in target muscles, number of impulses, session frequency, energy parameters, and application sites, and recent reviews have noted that ESWT protocols are not standardized. This study was designed to describe clinical changes following a single, clearly defined and reproducible rESWT protocol with anatomically predefined target points.

Design and Setting: Prospective, single-center, single-arm, open-label interventional study conducted at the Physical Medicine and Rehabilitation Clinic of Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Türkiye. All participants received the same intervention; there was no control or sham group.

Intervention: rESWT was delivered using a Modus ESWT device (İnceler Medikal, Ankara, Türkiye) to three muscles of the affected upper extremity: biceps brachii, flexor carpi radialis (FCR), and flexor carpi ulnaris (FCU). Each muscle received 2,000 impulses per session at a frequency of 5 Hz and a pressure of 1.5 bar (6,000 impulses per session in total). Treatment was administered twice weekly for 4 weeks, for a total of 8 sessions (48,000 impulses per participant). Target points were defined using anatomical reference lines based on the EUROMUSCULUS/USPRM spasticity approach: for the biceps brachii, 65% of the reference line between the coracoid process and the medial epicondyle; for the FCR, 35% of the reference line connecting the interepicondylar and interstyloid lines; and for the FCU, the 30% point on the ventral portion of the same reference line. Target sites were identified by palpation and marked on the skin before application, and coupling gel was used to ensure acoustic transmission. All applications were performed by a single operator according to the standardized protocol.

Concomitant Care: All participants had completed a conventional physiotherapy and rehabilitation program before rESWT. No physiotherapy or rehabilitation and no antispastic medication were given during the treatment and follow-up period.

Assessment Schedule: Assessments were performed at baseline (before the first rESWT session), week 4, and week 12. All Modified Ashworth Scale assessments were performed by the same investigator, who was not blinded.

Withdrawal: Participants who received botulinum toxin injections or started a physical therapy and rehabilitation program during the treatment or follow-up period, and participants who did not complete the rESWT sessions or the follow-up assessments, were withdrawn from the study.

Statistical Analysis: Of the 30 enrolled participants, 21 completed the full treatment course and all three assessments and were included in the analyses; missing data were not imputed. Changes across the three time points were analyzed with the Friedman test, and baseline-to-follow-up comparisons with the Wilcoxon signed-rank test, with Holm correction for multiple comparisons. Paired Hodges-Lehmann estimates with bootstrap 95% confidence intervals were calculated. No a priori sample size calculation was performed.

Ethics: The study was approved by the Ethics Committee of Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital (Decision No: 2025/214; Date: 11.06.2025) and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.

03

Conditions studied

  • Stroke

Keywords

  • rEswt
  • stroke
  • hemiplegia
  • spasticity
  • upper extremity
  • rehabilitation
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of hemiplegia following stroke
  • Minimum of 4 weeks elapsed since stroke onset
  • Modified Ashworth Scale (MAS) score ≥ 2 for elbow or wrist spasticity
  • Sufficient cognitive ability to follow simple commands
  • No botulinum toxin injection in the preceding 3 months
  • Willing to participate and signed form

Exclusion criteria

Exclusion Criteria:

  • Impaired consciousness or severe cognitive deficit
  • Systemic conditions contraindicating ESWT (active infection, , etc.)
  • Shoulder subluxation on the affected side
  • Skin integrity disruption at the application site
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Radial Extracorporeal Shock Wave Therapy (rESWT)

    Participants received radial extracorporeal shock wave therapy applied to three muscle groups of the affected upper extremity (biceps brachii, flexor carpi radialis, and flexor carpi ulnaris) at 2,000 impulses per muscle group, 5 Hz frequency, and 1.5 bar pressure, twice weekly for 4 weeks (8 sessions total)

    Device: Radial Extracorporeal Shock Wave Therapy (rESWT)

Interventions

  • DeviceRadial Extracorporeal Shock Wave Therapy (rESWT)

    rESWT was delivered to the biceps brachii, flexor carpi radialis, and flexor carpi ulnaris of the affected upper extremity. Parameters: 2,000 impulses per muscle group, 5 Hz, 1.5 bar. Eight sessions administered twice weekly over 4 weeks. Anatomical target points were standardized according to the EUROMUSCULUS/USPRM guideline.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Upper Extremity Spasticity Measured by the Modified Ashworth Scale

    Spasticity is assessed using the Modified Ashworth Scale (MAS), an ordinal scale measuring resistance to passive movement. Each of seven upper extremity movements (elbow flexion, elbow extension, forearm pronation, forearm supination, wrist flexion, wrist extension, and finger flexion) is graded individually on a 0 to 4 scale, where 0 (minimum) indicates no increase in muscle tone and 4 (maximum) indicates the affected part is rigid. Higher scores indicate greater spasticity (worse outcome).

    Time frame: Baseline, at 4 weeks and 12 weeks follow-up

  2. Change From Baseline in Fugl-Meyer Assessment Upper Extremity Motor Function Score

    Upper extremity motor function is assessed using the motor function domain of the upper extremity section of the Fugl-Meyer Assessment of Motor Recovery After Stroke (FMA-UE). It consists of 33 items evaluating reflex activity, voluntary movement within and out of synergy, wrist and hand function, and coordination/speed, each scored from 0 (cannot perform) to 2 (performs fully). Total scores range from 0 (minimum) to 66 (maximum). Higher scores indicate better motor function (better outcome).

    Time frame: Baseline, at 4 weeks and 12 weeks follow-up

Secondary outcomes

  1. Change from baseline in functional independence

    Functional independence is assessed using the Modified Barthel Index (MBI), which evaluates 10 activities of daily living. Total scores range from 0 to 100. Higher scores indicate greater independence (better outcome).

    Time frame: Baseline, at 4 weeks and at 12 weeks follow-up

  2. Change From Baseline in Pain Intensity Measured by the Visual Analog Scale

    Pain intensity in the affected upper extremity is assessed using the Visual Analog Scale (VAS) for pain, recorded as a single score. Scores range from 0 (minimum; no pain) to 10 (maximum; unbearable pain). Higher scores indicate greater pain intensity (worse outcome).

    Time frame: Baseline, at 4 weeks and at 12 weeks follow-up

  3. Change from baseline in stroke-specific quality of life

    Quality of life is assessed using the Stroke Specific Quality of Life Scale (SS-QOL), a 49-item instrument covering 12 domains, each item scored on a 1 to 5 Likert scale. Total scores range from 49 to 245. Higher scores indicate better quality of life (better outcome).

    Time frame: Baseline, at 4 weeks and at 12 weeks follow-up

  4. Change from baseline in depressive symptom severity

    Depressive symptom severity is assessed using the Beck Depression Inventory (BDI), a 21-item self-report scale with each item scored from 0 to 3. Total scores range from 0 to 63. Higher scores indicate greater depressive symptom severity (worse outcome).

    Time frame: Baseline, at 4 weeks, and at 12 weeks follow-up

  5. Change from baseline in proprioception

    Joint position sense of the affected upper extremity is assessed via standard clinical examination and categorized as intact, impaired, or not assessable.

    Time frame: Baseline, at 4 weeks and at 12 weeks follow-up

07

Study locations

1 site
  • Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
    Istanbul, Istanbul 34785, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in May 2026, 10 months.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 10 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Apr 2026 → May 2026 and completion Apr 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 15, 2026
StartActual
Jul 1, 2025
Primary completionActual
May 7, 2026was Apr 2026
CompletionActual
May 7, 2026was Apr 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 1, 2026→May 7, 2026
Oct 21, 2026
Study completion
Apr 1, 2026→May 7, 2026
Oct 21, 2026
Enrollment
21→30
Oct 21, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedModified Ashworth Scale (MAS) score ≥ 2 in at least one upper extremity joint movementfor elbow or wrist spasticity
Oct 21, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedChange from baselineFrom Baseline in upper extremity spasticityUpper Extremity Spasticity Measured by the Modified Ashworth ScaleTime frame: Baseline, at 4 weeks and 12 weeks follow-up
  • EditedChange from baselineFrom Baseline in upper extremity motor functionFugl-Meyer Assessment Upper Extremity Motor Function ScoreTime frame: Baseline, at 4 weeks and 12 weeks follow-up
Oct 21, 2026
Secondary outcomes
1 edited, 4 description edited
What changed in the outcomes
  • EditedChange from baselineFrom Baseline in pain intensityPain Intensity Measured by the Visual Analog ScaleTime frame: Baseline, at 4 weeks and at 12 weeks follow-up
  • DescriptionChange from baseline in depressive symptom severity: how it is measured was reworded
  • DescriptionChange from baseline in functional independence: how it is measured was reworded
  • DescriptionChange from baseline in proprioception: how it is measured was reworded
  • DescriptionChange from baseline in stroke-specific quality of life: how it is measured was reworded
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Apr 1, 2026→May 7, 2026
    Study completion Apr 1, 2026→May 7, 2026
    Enrollment 21→30
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedModified Ashworth Scale (MAS) score ≥ 2 in at least one upper extremity joint movementfor elbow or wrist spasticity
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline in upper extremity spasticityUpper Extremity Spasticity Measured by the Modified Ashworth ScaleTime frame: Baseline, at 4 weeks and 12 weeks follow-up
    • EditedChange from baselineFrom Baseline in upper extremity motor functionFugl-Meyer Assessment Upper Extremity Motor Function ScoreTime frame: Baseline, at 4 weeks and 12 weeks follow-up
    Secondary outcomes 1 edited, 4 description edited
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline in pain intensityPain Intensity Measured by the Visual Analog ScaleTime frame: Baseline, at 4 weeks and at 12 weeks follow-up
    • DescriptionChange from baseline in depressive symptom severity: how it is measured was reworded
    • DescriptionChange from baseline in functional independence: how it is measured was reworded
    • DescriptionChange from baseline in proprioception: how it is measured was reworded
    • DescriptionChange from baseline in stroke-specific quality of life: how it is measured was reworded
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07532187
Lead sponsor
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Jul 1, 2025
Primary completion
May 7, 2026
Completion
May 7, 2026
Last update
Oct 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion